SCHEMBL4516696

SCHEMBL4516696

CC(=O)c1sc(NC(N)=O)nc1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.66
GAA P10253 3/20 0.66
CYP1A2 P05177 1/20 0.66
CYP2C9 P11712 1/20 0.66
SMN1; SMN2 Q16637 7/20 0.64
ALDH1A1 P00352 5/20 0.64
RAB9A P51151 9/20 0.59
NPC1 O15118 8/20 0.59
KMT2A Q03164 5/20 0.59
MEN1 O00255 3/20 0.59
HTT P42858 2/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
DHODH Q02127 1/20 0.57
PKM P14618 2/20 0.57
NPSR1 Q6W5P4 1/20 0.56
KDM4E B2RXH2 2/20 0.55
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604834 0.86 RXFP1 (0.62) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL4473418 0.85 RXFP1 (0.70) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL2835357 0.85 RXFP1 (0.70) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL1911610 0.83 RXFP1 (0.62) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL4525376 0.80 ALDH1A1 (0.46) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL1592594 0.79 RXFP1 (0.62) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL27606981 0.79 RAB9A (0.56) RXFP1GAASMN1; SMN2ALDH1A1RAB9A
SCHEMBL28508629 0.79 ALDH1A1 (0.77) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
SCHEMBL7923956 0.78 ALDH1A1 (0.70) RXFP1GAACYP1A2CYP2C9SMN1; SMN2
Hydrochloric Acid SCHEMBL14053819 0.78 RXFP1 (0.60) RXFP1GAACYP1A2CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150561-B2 Thiazole derivatives and use thereof MERCK SERONO S.A. (CH) 2015-10-06 US disclosed
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO S.A. (CH) 2014-08-14 US disclosed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US disclosed
EP-1709019-B1 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS (AN) 2007-08-08 EP disclosed
EP-1709019-A2 THIAZOLE DERIVATIVES AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2006-10-11 EP disclosed
WO-2005068444-A2 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF PF4, TEC, PDGFRB RXFP1 2341/4885GAA 4479/4885CYP1A2 2522/4885
US-20090029998-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC RXFP1 1838/4885GAA 3788/4885CYP1A2 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.